Skip to main content

Table 2 Association of NLR at baseline, at 6-weeks, and change at week 6 (±2 weeks) with treatment outcomes in multivariable Cox and Logistic regression models

From: Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

  ORR (CR + PR) PFS OS
  Total N/ N response Adjusted-ORb p-value Total N/ N event Adjusted-HRb p-value Total N/ N event Adjusted-HRb p-value
Continuous Ln(NLR) [baseline] 142/44 0.49 (0.22–1.09) 0.081 142/96 1.80 (1.14–2.86) 0.012 142/51 1.70 (0.99–2.94) 0.056
Continuous Ln(NLR) [6-weeks]a 134/44 0.22 (0.10–0.52) 0.001 117/72 3.61 (2.21–5.88) <0.001 134/46 2.51 (1.71–3.69) <0.001
NLR-change [6-weeks]a
 Decrease ≥25% 28/12 1.52 (0.49–4.68) 0.112 27/13 0.55 (0.26–1.18) <0.001 28/6 0.33 (0.12–0.88) 0.004
 No change 58/21 1.00 (reference)   53/30 1.00 (reference)   58/18 1.00 (reference)  
 Increase ≥25% 48/11 0.45 (0.18–1.16)   37/29 2.60 (1.53–4.39)   48/22 1.57 (0.83–2.99)  
  1. Abbreviations: ORR objective response rate, CR complete response, PR partial response, OR odds ratio, PFS progression free survival, HR hazard ratio, OS overall survival
  2. aLandmark approach was used where OS and PFS were calculated from 6 weeks after therapy initiation. Patients who progressed before the 6 week landmark time were excluded for PFS analysis
  3. bAdjusted for line of therapy, number of IMDC risk factors, histology (clear cell RCC vs non-clear cell RCC); baseline Ln(NLR) was also included as a covariate for the analysis of NLR change at 6 weeks. Boldface numerical values indicate statistically significant results